Home Newsfeeds Evercore ISI Group Upgrades Enanta Pharmaceuticals to Outperform, Announces $62 Price Target

Evercore ISI Group Upgrades Enanta Pharmaceuticals to Outperform, Announces $62 Price Target

Evercore ISI Group analyst Liisa Bayko upgrades Enanta Pharmaceuticals (NASDAQ:ENTA) from In-Line to Outperform and announces $62 price target.

byBenzinga Newsdesk

July 6, 2022

1 minute read

Evercore ISI Group analyst Liisa Bayko upgrades Enanta Pharmaceuticals (NASDAQ:ENTA) from In-Line to Outperform and announces $62 price target.

B of A Securities Reinstates Underperform on Altice USA, Announces $3.5 Price Target

By Benzinga Newsdesk

December 8, 10:10 AM

B of A Securities analyst Jessica Reif Cohen reinstates Altice USA (NYSE:ATUS) with a Underperform and announces $3.5 price target.

ATUS

Spooktacular Halloween With Cannabis: Tricks And Treats To Elevate Your Bash

By Joana Scopel

October 30, 10:37 PM

Halloween is almost here, and if you're in search of some last-minute ways to make your spooky celebration even more memorable, we've got you covered!

CGC

Johnson & Johnson, A. O. Smith And This Health Insurer On CNBC’s ‘Final Trades’

By Priya Nigam

April 26, 8:12 AM

On CNBC’s "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management said A. O.

AOS

$1000 Invested In Thermo Fisher Scientific 15 Years Ago Would Be Worth This Much Today

By Benzinga Insights

January 11, 1:34 PM

Thermo Fisher Scientific (NYSE:TMO) has outperformed the market over the past 15 years by 9.62% on an annualized…

TMO

Evercore ISI Group Upgrades Enanta Pharmaceuticals to Outperform, Announces $62 Price Target

Related Posts

B of A Securities Reinstates Underperform on Altice USA, Announces $3.5 Price Target

Spooktacular Halloween With Cannabis: Tricks And Treats To Elevate Your Bash

Johnson & Johnson, A. O. Smith And This Health Insurer On CNBC’s ‘Final Trades’

$1000 Invested In Thermo Fisher Scientific 15 Years Ago Would Be Worth This Much Today